Actively Recruiting
Open-Label Extension for Participants Benefiting from Secukinumab After Completing Previous Novartis Trials
Led by Novartis Pharmaceuticals · Updated on 2026-10-13
1000
Participants Needed
171
Research Sites
9 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on participants with autoimmune and inflammatory conditions who have previously taken part in a Novartis study involving secukinumab. It aims to evaluate the long-term safety of secukinumab in those who continue to benefit from the treatment but cannot access the marketed version. The study is a Phase 4, open-label extension designed to provide ongoing assessment of this medication. Participants will receive secukinumab injections under the skin at doses of 75 mg, 150 mg, or 300 mg every four weeks, depending on their previous treatment dose in the parent trial. Pediatric dosing will be limited according to weight categories and prior evaluated maximum doses. Investigators can adjust doses based on clinical needs and health authority guidance. This study involves a single group receiving secukinumab with no placebo or comparator. During the study, participants will be monitored for up to two years to assess the occurrence of any adverse or serious adverse events. The trial will involve regular evaluations to track the participants safety while continuing secukinumab treatment. The total duration for participation can extend until the study ends in 2030, with ongoing safety assessments throughout this period.
CONDITIONS
Brief Title
Secukinumab Open Label Roll-over Extension Protocol
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here